A Phase 3 interventional study of Tegoprazan/Amoxicillin/Clarithromycin and Lansoprazole/Amoxicillin/Clarithromycin in Helicobacter Pylori Infection, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-05-08.
Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy (tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy (lansoprazole, amoxicillin, and clarithromycin; hereinafter LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan after oral administration of the therapy for 7 days, twice daily in H. pylori positive patients.
This is a randomized, double blind, active controlled, multicenter, Phase 3 study to demonstrate the non-inferiority of tegoprazan triple therapy (TAC) to lansoprazole triple therapy (LAC) in terms of H. pylori eradication rate and to evaluate the safety of tegoprazan in H. pylori positive patients after oral administration of therapy for 7 days, twice daily. After the treatment, UBT test will be conducted to confirm the Helicobacter pylori eradication.
HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Tegoprazan 50 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
Drug: Tegoprazan/Amoxicillin/Clarithromycin
Lansoprazole 30 mg / Amoxicillin 1000 mg / Clarithromycin 500 mg
Drug: Lansoprazole/Amoxicillin/Clarithromycin
Drug pages: Tegoprazan · Amoxicillin · Clarithromycin
Tegoprazan 50 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
Also known as: Tegoprazan triple therapy (TAC)
Drug pages: Lansoprazole · Amoxicillin · Clarithromycin
Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
Also known as: Lansoprazole triple therapy (LAC)
H. pylori eradication rate
Subjects will be considered to succeed in achieving H. pylori eradication if subjects's negative UBT test.
Time frame: 6 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jun 2018 to primary completion in Dec 2019, 18 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tegoprazan · Amoxicillin · Clarithromycin